Compare Amgen, Inc. (AMGN) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Extra Space Storage, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Extra Space Storage, Inc. trades at $145.13 (market cap $30.41B). The key difference: Amgen, Inc. is far larger — about 6.4× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.5%). Which is the better fit depends on your goals.
| AMGN | EXR | |
|---|---|---|
Market Cap | $196.12B | $30.41B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $152.75 |
52-Week Low | $271.18 | $126.67 |
Enterprise Value | $241.41B | $44.21B |
Dividend Yield | 2.77% | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Extra Space Storage (EXR) trades at $143.96, up 0.9% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $3.38B and net income of $974M, though profitability margins have moderated from prior peaks. Recent news includes a $550M senior notes offering and the release of its 2025 sustainability report, indicating ongoing capital management and operational focus.
Outlook is mixed: analyst consensus is a Buy with a $155.88 price target, but technical weakness and expense growth pose near-term risks. The stock offers income via a $1.62 dividend, yet investors face headwinds from competitive pressures and potential occupancy declines. Valuation remains elevated with a P/E of 32.35, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
